GovChime
Notice ID: 905d5e04b13a42ab9fdffb7382700a5dPresolicitationCancelled on SAM.gov

Piflufolastat F-18 injection drugs (Pylarify) from Lantheus (Notice of Intent to sole source)

Cancelled on SAM.gov (notice posted September 29, 2026). Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:00 AM EDT
Posted
September 29, 2026
Notice type
Presolicitation
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH - CC
Place of performance
Bethesda, Maryland, 20814
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
NOI-27-000004
Notice ID
905d5e04b13a42ab9fdffb7382700a5d

Description

Acquisition Description:

This is a Notice of Intent, not a request for proposal.  The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Progenics Pharmaceuticals Inc.

The National Institute of Health, Clinical Center (NIH-CC)’s has the Nuclear Pharmacy (CC NP) department (collectively “Program”) that purchases and compounds radiopharmaceuticals (radioactive drugs) on a daily basis for life-saving clinical nuclear medicine procedures. This is essential for the NIH Clinical Center to achieve optimal patient care. These radiopharmaceuticals are United States Food and Drug Administration (FDA) approved drugs for use in patients. They are also radioactive materials that are regulated by the United States Nuclear Regulatory Commission (US NRC) through the NIH radioactive material license (RAM) administered by the NIH Radiation Safety Office (RSO). Only RSO certified Nuclear Medicine personnel can order these radiopharmaceuticals directly for patient use. Each radiopharmaceutical is time sensitive because of the rapid radiation decay. Because of their short useful half-lives, they cannot be ordered in advance for storage. They must be properly compounded, dispensed, calibrated and delivered for a specific patient at a specific time on a specific date on a daily basis.

The purpose is to procure compounded piflufolasta F-18 in patient ready unit doses (UDs) from an authorized nuclear pharmacy for the use by the NIH Nuclear Medicine, Department of Radiology and Imaging Sciences to diagnose and treat diseases as required by necessary patient care protocols at the NIH Clinical Center. This new radioactive drug is vital to the NIH Clinical Center mission.

The product is owned and developed by Lantheus Medical/Progenics Pharmaceuticals (now merged as one company). Progenics Pharmaceuticals Inc uses Lantheus’ Federal Supply Schedule contract on contract 36F79719D0170.

Justification and other information:

This requirement will be sole sourced to Progenics Pharmaceuticals Inc. under FAR 8.405-6 (b): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. This notice is being made on SAM.gov instead of GSA Ebuy because the GSA Ebuy category “65 I B PHARMACEUTICALS AND DRUGS” states that “This SIN is not available through GSA Advantage.”

Lantheus Medical Imaging (a company of Lanntheus Holding, Inc.) is the developer and intellectual property owner of Piflufolastat F-18 injection drugs (Pylarify) in the United States. More specifically, Progenics Pharmceuticals had been developing this drug and Lantheus merged Progenics Pharmaceuticals. Progenics Pharmaceuticals Inc is the only local authorized commercial nuclear pharmacy authorized by Lanthesus Medical Imaging to compound, prepare, delivery and invoice for these drugs. They use the Federal Supply Schedule contract on contract 36F79719D0170, and they are the designated authorized vendor for our area.

Only this drug can be used for Program’s patient care and research and Program has been using these drugs for years in ongoing projects and patient care. Only qualified vendors that meet the FDA and US NRC regulations can provide these radiopharmaceuticals for compounding and dispensing at NIH Nuclear Pharmacy to NIH Clinical Center patients. Thus, only Progenics Pharmaceuticals Inc. is the sole authorized provider of these drugs.

Indefinite Delivery/Indefinite Quantity (IDIQ) Requirement:

150x to 230x Qty of PYLARIFY piflufolastat F-18 injections

4x Qty for PYLARIFY unused doses fees

Base Year

Option Year 1

Option Year 2

Option Year 3

Option Year 4

Place of Performance or Delivery:

The contract period of performance is 10/01/2026 – 09/30/2027 for the base year.

Option Years:

10/01/2027 – 09/30/2028

10/01/2028 – 09/30/2029

10/01/2029 – 09/30/2030

10/01/2030 – 09/30/2031

This requirement will be awarded on GSA Contract #36F79719D0170.

Place of Performance: NIH Clinical Center in Bethesda, MD

The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 and/or FAR 8.405-6 - only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.  All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-000004) by 10:00 AM eastern standard time on 09/29/2026 to: lu-chang.lu@nih.gov

All responses received by the closing date of this synopsis will be considered by the Government.  A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

Files (2)

  • 1. JOFOC for Pylarify FY2027_redacted.pdf

    185 KBAdded in Presolicitation version 1Posted
    Download
  • 1. STATEMENT OF WORK Pylarify FY2027_Redacted.pdf

    139 KBAdded in Presolicitation version 1Posted
    Download

Lifecycle

  1. 1
    Version 1PresolicitationArchived

    Piflufolastat F-18 injection drugs (Pylarify) from Lantheus (Notice of Intent to sole source)

    Notice e0c5bd53c85640ccaaaa6b85ffd21ee4 on SAM.gov

  2. 2
    Version 2PresolicitationCancelledArchivedCurrent

    Piflufolastat F-18 injection drugs (Pylarify) from Lantheus (Notice of Intent to sole source)

    Notice 905d5e04b13a42ab9fdffb7382700a5d on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
74%
Pre-Solicitation11/11/2026
INTENT TO SOLE SOURCE This notice of intent to sole source is to make a sole award firm-fixed-price contract. The Department of Veterans Affairs Long Beach Healthcare System, located at 5901 East 7th Street, Long Beach, CA 90822 is issuing this notice of intent to inform industry contractors of the Government s intent to execute a sole source delivery order in accordance with Revolutionary FAR Overhaul (RFO) Part 8.401, GSAM/R 538.7104-3(b)(ii) Only one source available, and GSAM/R 538.7104-4 Items Peculiar to one manufacturer. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing with a size standard of 1,300 Employees. A Long Beach Healthcare System Nuclear Medicine department has a requirement for radiopharmaceuticals injections of Pylarify (piflufolastat F18). This is an advanced diagnostic imaging agent used with Positron Emission Tomography (PET)/Computed Tomography (CT) scans to find tumors in the prostate which identify the prostate-specific membrane antigen (PSMA), as well as in lymph nodes, bones, and other organs. The intended contractor is Progenics Pharmaceuticals, Inc located at 331 Treble Cove Road, N. Billerica, MA 01862. Requested Pylarify (piflufolastat F18) is available under the existing VA National Acquisition Center Contract (NAC) Federal Supply Schedule (FSS)# 36F79725D0093, effective from 04/01/2025 through 03/31/2030. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. THIS IS NOT A SOLICITIATION. No award will be made as a result of any quotations received in response to this notice. The intent of this notice is for informational purposes only. A determination by the Government not to compete this action based on this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any responses to this notice must show clear and compelling evidence that the responding company can provide the same items, and that competition will be advantageous to the Government. All inquiries and correspondence must be addressed in writing via e-mail to Melissa Ramirez, Contracting Specialist, at Melissa.Ramirez8@va.gov with VA LB Pylarify Intent to Sole Source Response in the subject line. Telephone requests will not be honored. All interested parties who are responsible, certified, and capable may identify their interest and may submit a capabilities statement no later than November 3rd, 2026 10:00 AM Pacific Local Time. The interested parties bear full responsibility to ensure complete transmission and timely receipt.
72%
Special Notice11/03/2026
68%
AwardedOpen
PRE-SOLICITATION NOTICE: The VA Enterprise Procurement Office intends to issue Request for Proposal (RFP) 36E79726R0041 for a restricted procurement for Sodium Bicarbonate Injection Vials, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD) (inclusive of Tricare Mail Order Pharmacies (TMOPs)), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). VA proposes to solicit for and award a firm-fixed requirements-type contract for sodium bicarbonate for injection (sodium bicarbonate) that is limited to suppliers with product manufactured in the United States in accordance with FAR 6.103-3 Industrial Mobilization: engineering, developmental, or research capability: or expert services. VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere on top of the successful offeror/contractor s label. Glass bottles ARE acceptable. All tablets/capsules/carton/bottles must be compatible with automated dispensing units (Baxter ATC Canisters, Opti-fill, etc.) Solicitation # 36E79726R0041 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about October 21, 2026, with a tentative closing date of November 18, 2026. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at Sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Teresa Hussain. Questions can be e-mailed to Teresa.Hussain@va.gov. The estimated annual requirements are as follows: REQUIREMENT DESCRIPTION ITEM DESCRIPTION PACKAGE SIZE (VIALS) TOTAL ESTIMATED ANNUAL USAGE (Bottles) 1 SODIUM BICARBONATE 84MG/ML INJ, 50ML VIAL 1 65,587
67%
Pre-Solicitation10/21/2026
M5-Q50A-03-R8: 65IB Drugs, Pharmaceuticals & Hematology Related Products Solicitation Refreshment
67%
Pre-Solicitation06/21/2023

Additional Details

Solicitation Number

NOI-27-000004

Archive Date

Oct 14, 2026

Office Address

BETHESDA, MD, 20892